Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

New

MK-886

A leukotriene antagonist
Catalog #: B2517
SKU-Size Size Price Qty
B2517-5 5 mg
$115.00
B2517-25 25 mg
$455.00
More Sizes Get Quote

Product Details

Alternate Name 3-[3-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-yl-indol-2-yl]-2,2 -dimethyl-propanoic acid; MK886; L-663,536; L663,536
Appearance Crystalline solid
CAS # 118414-82-7
Molecular Formula C₂₇H₃₄ClNOS
Molecular Weight 472.08
Purity ≥98%
Solubility >40 mg/ml in DMSO
SMILES CC(C)C1=CC2=C(C=C1)N(C(=C2SC(C)(C)C)CC(C)(C)C(=O)O)CC3=CC=C(C=C3)Cl
InChi InChI=1S/C27H34ClNO2S/c1-17(2)19-10-13-22-21(14-19)24(32-26(3,4)5)23(15-27(6,7)25(30)31)29(22)16-18-8-11-20(28)12-9-18/h8-14,17H,15-16H2,1-7H3,(H,30,31)
InChi Key QAOAOVKBIIKRNL-UHFFFAOYSA-N
PubChem CID 3651377
Handling Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Storage Conditions -20ºC
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

MK-886 is a potent and selective inhibitor of 5-lipoxygenase-activating protein (FLAP) that prevents 5-lipoxygenase activation in vivo and inhibits leukotriene biosynthesis in leukocytes (IC₅₀ of 2.5 nM). MK-886 also inhibits cyclooxygenase-1 (COX-1) activity and suppresses platelet aggregation.


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.